Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA) (VICTORIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02730923
Recruitment Status : Recruiting
First Posted : April 7, 2016
Last Update Posted : June 12, 2019
Sponsor:
Information provided by (Responsible Party):
Centre Leon Berard

Tracking Information
First Submitted Date  ICMJE March 18, 2016
First Posted Date  ICMJE April 7, 2016
Last Update Posted Date June 12, 2019
Study Start Date  ICMJE April 2016
Estimated Primary Completion Date November 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 6, 2016)
  • Number of patients with severe toxicities occurring during the first 8 weeks of follow-up assessed using National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) V4 [ Time Frame: during the first 8 weeks of follow up ]
    Severe toxicities defined as
    • Any grade ≥ 4 treatment related toxicity
    • Any grade≥ 3 treatment related toxicity lasting more than 7 days
  • The 8-week non progression rate using RECIST v1.1 to assess tumor response to treatment [ Time Frame: 8 weeks after start of treatment ]
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 31, 2016)
  • Number of patients with AE graded using CTCAE V4 [ Time Frame: For each participant, up to 30 days after the last dose of treatment (up to 3 years) ]
  • Progression-free survival (PFS) defined as the duration of time from start of treatment to time of progression or death, whichever occurs first [ Time Frame: up to 3 years ]
  • Overall survival (OS) defined as the duration of time from start of treatment to time of death. [ Time Frame: 3 years ]
  • Best response rate defined as (percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to RECIST V1.1) [ Time Frame: Up to 3 years ]
  • Duration of objective response as per RECIST v1.1 [ Time Frame: Up to 3 years ]
  • Area under the curve (AUC) of AZD2014 [ Time Frame: Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later. ]
  • Apparent clearance of AZD2014 [ Time Frame: Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later ]
  • The accumulation of the 47S precursor ribosomal ribonucleic acid (rRNA), which reflects RNA polymerase I activity analysed by fluorescence in situ hybridization (FISH) [ Time Frame: Baseline and 8 weeks after treatment ]
  • The expression of components of rRNA methylation complex analysed by real time quantitative PCR (RTqPCR) [ Time Frame: Baseline and 8 weeks after treatment ]
  • The levels of circulating anti-fibrillarin (anti-FBL) autoantibody on serum samples by Elisa assays [ Time Frame: Baseline and 8 weeks after treatment ]
  • Levels of expression of fibrillarin assessed by immunohistochemistry (IHC) [ Time Frame: Baseline and 8 weeks after treatment ]
  • Levels of expression of nucleolin assessed by IHC [ Time Frame: Baseline and 8 weeks after treatment ]
  • Levels of expression of protein B23 assessed by IHC [ Time Frame: Baseline and 8 weeks after treatment ]
  • Levels of expression of upstream binding factor (UBF) assessed by IHC [ Time Frame: Baseline and 8 weeks after treatment ]
  • Levels of expression of phosphorylated UBF assessed by IHC [ Time Frame: Baseline and 8 weeks after treatment ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 6, 2016)
  • Number of patients with AE graded using CTCAE V4 [ Time Frame: For each participant, up to 30 days after the last dose of treatment (up to 3 years) ]
  • Progression-free survival (PFS) defined as the duration of time from start of treatment to time of progression or death, whichever occurs first [ Time Frame: up to 3 years ]
  • Overall survival (OS) defined as the duration of time from start of treatment to time of death. [ Time Frame: 3 years ]
  • Best response rate defined as (percentage of patients with complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD) according to RECIST V1.1) [ Time Frame: Up to 3 years ]
  • Duration of objective response as per RECIST v1.1 [ Time Frame: Up to 3 years ]
  • biomarkers of AZD2014 activity in tumor and blood samples that correlate with clinical outcomes [ Time Frame: 8 weeks ]
  • Area under the curve (AUC) of AZD2014 [ Time Frame: Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later. ]
  • Apparent clearance of AZD2014 [ Time Frame: Week 1 Day 1: pre-dose, 2h and 6-8 hours later and Week 2 Day 1: pre-dose, 2h and 6-8 hours later ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
Official Title  ICMJE A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Brief Summary

The investigators hypothesize that the dual inhibition of mTORC1/mTORC2 by AZD2014 combined with inhibition of aromatase enzyme by anastrozole will act synergistically and may be an interesting therapeutic option for endometrial cancer with a manageable toxicity profile.

The investigators proposal is to conduct a multicenter, 2-step, randomized, Phase I/II trial to evaluate the safety and efficacy of a combination treatment associating anastrozole to AZD2014 in advanced endometrial cancer patients.

The study is divided in 2 steps :

  • A safety run-in phase aiming to evaluate the safety of the proposed combination AZD2014 + anastrozole (Arm A) versus anastrozole alone (Arm B). No dose escalation is scheduled (doses are based on maximum tolerated dose (MTD) defined for AZD2014 and the summary of product characteristics (SPC) of anastrozole). However, dose de-escalation for AZD2014 will be applied in case of toxicity.
  • A two-stage randomized Phase II part aiming to evaluate the clinical benefit of the AZD2014 + anastrozole (Arm A) combination therapy versus anastrozole (Arm B).
Detailed Description

TREATMENT PLAN :

Following randomisation patients will receive Arm A : AZD2014 plus anastrozole or Arm B: anastrozole alone AZD2014 will be administered with an intermittent schedule i.e. 125 mg bis in die (BID) intermittent with 2 days on followed by 5 days off per week for a total weekly dose of 500 mg/week (250mg D1 and D2, 5 days off) Anastrozole will be administered at the standard dose defined in the SPC i.e. 1mg/d, per os, continuously.

Both treatment will be administered until progressive disease (PD), unacceptable toxicity or willingness to stop.

STATISTICS :

A total of 72 patients will be randomized in the study.

Safety run-in Phase on the first 9 patients randomized - As no dose escalation will be performed, the safety will be evaluated following the treatment and 8-week follow-up of the first 6 patients by the experimental association AZD2014+anastrozole (experimental arm). By similarity to a classic 3+3 design, based on binomial probabilities, there is a 90% probability of observing one or more patients with a toxicity event, if that event occurs in at least 32% of the target population. Assuming a 2:1 randomization ratio, a total of 9 patients (Arm A - Experimental: 6 patients, Arm B - Control: 3 patients) will be enrolled in this safety run-in phase and will be included in the evaluation of Phase II part.

Phase II The sample size calculation was based on a Simon optimal two-stage design, with a minimum success (8-week non progression) rate considered of interest p1=60% and an uninteresting rate p0=40%. Assuming a type I error alpha of 0.05 and 80% power, 46 evaluable patients are needed in the experimental arm to reject the null hypothesis H0: p≤p0 versus the alternative hypothesis H1: p ≥ p1 in a unilateral situation (16 patients in Stage I and 30 additional patients in Stage II).

With a 2:1 randomization and based on the assumption that 5% of the patients may be non-evaluable, a total of 72 patients will be included in the study : 48 patients in Arm A - experimental and 24 patients in Arm B - control).

DATA ENTRY, DATA MANAGEMENT AND STUDY MONITORING All the data concerning the patients will be recorded in the electronic case report form (eCRF) throughout the study. serious adverse event (SAE) reporting will be also paper-based by e-mail and/or Fax.

The sponsor will perform the study monitoring and will help the investigators to conduct the study in compliance with the clinical trial protocol, Good Clinical Practices (GCP) and local law requirements.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Endometrial Carcinoma
  • Metastatic Carcinoma
  • Hormone Receptor Positive Tumor
Intervention  ICMJE
  • Drug: AZD2014

    Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone

    Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.

    Route of Administration Oral

    Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))

    Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.

  • Drug: Anastrozole

    Therapeutic Class Aromatase inhibitor

    Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.

    Route of Administration Oral

    Dosage regimen

    1 mg tablet once a day

    Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request.

    Other Name: Arimidex
Study Arms  ICMJE
  • Experimental: Arm A: AZD2014 plus anastrozole
    Interventions:
    • Drug: AZD2014
    • Drug: Anastrozole
  • Active Comparator: Arm B: anastrozole alone
    Intervention: Drug: Anastrozole
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 6, 2016)
72
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2020
Estimated Primary Completion Date November 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Postmenopausal female patient at the time of consent
  • Histologically-confirmed diagnosis of advanced or recurrent endometrial carcinoma, not amenable to curative treatments. Carcinosarcoma are not eligible.
  • Documented estrogen receptor and/or progesterone receptor positive endometrial cancer. Hormone receptor positivity is defined according to routine practice at each participating site.
  • Availability of a pre-treatment tumor sample (archival formalin-fixed paraffin-embedded (FFPE) block or fresh biopsy if feasible) and presence of at least one biopsiable tumor lesion for on-treatment biopsy
  • Documented disease progression after no more than one prior first-line chemotherapy regimen and/or more than 2 lines endocrine therapy in the metastatic setting
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 and minimum life expectancy of 8 weeks
  • At least one measurable lesion according to response evaluation criteria in solid tumor (RECIST 1.1)
  • Adequate bone marrow, renal and liver function as shown by:

    • Absolute neutrophil count > 1.5 x 109/L, Platelets > 100 x 109/L, Hemoglobin (Hb) >9 g/dL
    • Serum bilirubin ≤ 1.5 upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase ≤ 2.5 ULN (≤ 5 ULN in patients with liver metastases)
    • Creatinine clearance > 50 mL/min (using Cockcroft formula, or MDRD formula for patients over 65 years Appendix 3 - Creatinine Clearance)
  • Fasting serum cholesterol ≤ 300 mg/dL (7.75 mmol/L) AND fasting triglycerides ≤ 2.5 ULN (lipid-lowering drugs allowed),
  • Fasting plasma glucose ≤7 mmol/L (126 mg/dL)
  • Recovered from prior significant treatment-related toxicity i.e. no persistent treatment-related toxicity > Grade 1 as per Common Terminology Criteria for Adverse Events (CTCAE) v4.3, except grade 2 alopecia, grade 2 anemia but with Hb >9 g/dL.
  • Minimal wash-out period before the start of the study drugs for the following treatments:

    • Any anti-cancer treatment approved or investigational medicinal product :> 21 days
    • Any chemotherapy, radiation therapy, androgens : > 21 days (not including palliative radiotherapy at focal sites).
    • Any monoclonal antibody therapy: > 4 weeks
    • Major surgery: > 4 weeks
    • Minor surgery (excluding tumour biopsies) >14 days.
    • Any haemopoietic growth factors (e.g., filgrastim [granulocyte colony-stimulating factor (G-CSF)], sargramostim [granulocyte-macrophage colony-stimulating factor (GM-CSF)]): > 14 days
    • Vaccinated with live, attenuated vaccines : > 4 weeks.
    • Sensitive or narrow therapeutic range substrates of the drug metabolising organic anion-transporting polypeptide 1B1 (OATP1B1), organic anion-transporting polypeptide 1B3 (OATP1B3), MATE1 and MATE2K : see the appropriate wash-out period (a minimum of 5 x reported elimination half-life) in Appendix 5 - Restricted CYP and transporter related co-medications)
  • Potent or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP - Restricted CYP and transporter related co-medications
  • Patient willing to follow sunlight-protection measures. Patients should be advised of the need for sunlight protection measures during administration of AZD2014, and should be advised to adopt such measures for a period of 3 months after receiving their final dose of AZD2014.
  • Patient able and willing to provide informed consent with ability to understand and willingness for follow-up visits.
  • Covered by a medical insurance

Exclusion Criteria:

  • Patient pre-treated by a non-steroidal aromatase inhibitor
  • Active uncontrolled or symptomatic central nervous system metastases or spinal cord compression
  • Clinically relevant abnormal levels of potassium or sodium.
  • Use of any forbidden concomitant treatment during the treatment period:

    • Any anti-cancer treatment (approved or investigational) not mentioned in the protocol
    • Chronic treatment with corticosteroids or other immunosuppressive agents. Stable low dose of corticosteroids are allowed (unless contra-indicated) provided that they were initiated before the last disease progression or were started at least 4 weeks prior to study treatment. Topical or inhaled corticosteroids are allowed.
    • Potent or moderate inhibitors or inducers of CYP3A4/5, Pgp (MDR1) and BCRP (see Appendix 5 - Restricted CYP and transporter related co-medications)
    • Sensitive or narrow therapeutic range substrates of the drug transporters OATP1B1, OATP1B3, MATE1 and MATE2K outside the wash out period and restrictions presented in Appendix 5 - Restricted CYP and transporter related co-medications)
  • Patient with known hypersensitivity to anastrozole or to any of the excipients (Lactose monohydrate, Povidone, Sodium starch glycollate, Magnesium stearate, Hypromellose, Macrogol 300, Titanium dioxide)
  • History of hypersensitivity to active or inactive excipients of AZD2014 or drugs with a similar chemical structure or class to AZD2014
  • History of other malignancies except for basal cell or squamous cell skin cancer, in situ cervical cancer, unless they have been disease-free for at least five years
  • Patient who has any severe and/or uncontrolled medical conditions such as:

    • Recent history of specific cardiovascular events, or laboratory parameters that may affect cardiac parameters including : unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤6 months prior to start of study drug, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease; Symptomatic congestive heart failure of New York heart Association Class III or IV
    • Mean resting corrected QT interval (QTc), calculated using Fridericia's formula, > 470 msec obtained from 3 electrocardiograms (ECGs), family or personal history of long or short QT syndrome, Brugada syndrome or known history of QTc prolongation or Torsade de Pointes within 12 months of the patient entering in the study
    • Abnormal cardiac function at baseline :left ventricular ejection fraction (LVEF) <50%
    • Any evidence of interstitial lung disease and uncompensated respiratory conditions.
    • Active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active or chronic hepatitis (i.e. quantifiable hepatitis B virus (HBV-DNA) and/or positive HbsAg, quantifiable hepatitis C virus (HCV-RNA)),
    • Active, bleeding diathesis
    • Current refractory nausea and vomiting, chronic gastro-intestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD2014.
    • Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
    • Type 1 and uncontrolled Type 2 diabetes
    • Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi Syndrome or renal tubular acidosis.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Pierre-Etienne HEUDEL, MD 04 78 78 27 57 pierre-etienne.heudel@lyon.unicancer.fr
Listed Location Countries  ICMJE France
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02730923
Other Study ID Numbers  ICMJE VICTORIA (ET150036)
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Centre Leon Berard
Study Sponsor  ICMJE Centre Leon Berard
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Pierre-Etienne HEUDEL, MD Centre Leon Berard
PRS Account Centre Leon Berard
Verification Date June 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP